Livnat Jerby-Arnon
Cited by
Cited by
Perturb-Seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens
A Dixit, O Parnas, B Li, J Chen, CP Fulco, L Jerby-Arnon, ND Marjanovic, ...
Cell 167 (7), 1853-1866. e17, 2016
Predicting selective drug targets in cancer through metabolic networks
O Folger, L Jerby, C Frezza, E Gottlieb, E Ruppin, T Shlomi
Molecular systems biology 7 (1), 501, 2011
Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase
C Frezza, L Zheng, O Folger, KN Rajagopalan, ED MacKenzie, L Jerby, ...
Nature 477 (7363), 225-228, 2011
Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism
J Livnat, S Tomer, E Ruppin
Molecular systems biology 6 (1), 2010
A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade
L Jerby-Arnon, P Shah, MS Cuoco, C Rodman, MJ Su, JC Melms, ...
Cell 175 (4), 984-997. e24, 2018
Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality
L Jerby-Arnon, N Pfetzer, YY Waldman, L McGarry, D James, E Shanks, ...
Cell 158 (5), 1199-1209, 2014
Fumarate induces redox-dependent senescence by modifying glutathione metabolism
L Zheng, S Cardaci, L Jerby, ED MacKenzie, M Sciacovelli, TI Johnson, ...
Nature communications 6 (1), 1-12, 2015
Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer
L Jerby, L Wolf, C Denkert, GY Stein, M Hilvo, M Oresic, T Geiger, ...
Cancer research 72 (22), 5712-5720, 2012
Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling
L Jerby, E Ruppin
Clinical Cancer Research 18 (20), 5572-5584, 2012
Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease
T Hyötyläinen, L Jerby, EM Petäjä, I Mattila, S Jäntti, P Auvinen, ...
Nature Communications 7 (1), 1-9, 2016
Harnessing synthetic lethality to predict the response to cancer treatment
JS Lee, A Das, L Jerby-Arnon, R Arafeh, N Auslander, M Davidson, ...
Nature communications 9 (1), 1-12, 2018
A single-cell and single-nucleus RNA-seq toolbox for fresh and frozen human tumors
M Slyper, CBM Porter, O Ashenberg, J Waldman, E Drokhlyansky, ...
Nature medicine 26 (5), 792-802, 2020
A single-cell landscape of high-grade serous ovarian cancer
B Izar, I Tirosh, EH Stover, I Wakiro, MS Cuoco, I Alter, C Rodman, ...
Nature medicine 26 (8), 1271-1279, 2020
IL-33 signaling alters regulatory T cell diversity in support of tumor development
A Li, RH Herbst, D Canner, JM Schenkel, OC Smith, JY Kim, M Hillman, ...
Cell reports 29 (10), 2998-3008. e8, 2019
Genome‐wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy
AD Sahu, J S Lee, Z Wang, G Zhang, R Iglesias‐Bartolome, T Tian, Z Wei, ...
Molecular systems biology 15 (3), e8323, 2019
A distinct transcriptional program in human CAR T cells bearing the 4-1BB signaling domain revealed by scRNA-seq
AC Boroughs, RC Larson, ND Marjanovic, K Gosik, AP Castano, ...
Molecular Therapy 28 (12), 2577-2592, 2020
Longitudinal single cell profiling of regulatory T cells identifies IL-33 as a driver of tumor immunosuppression
A Li, RH Herbst, D Canner, JM Schenkel, OC Smith, JY Kim, M Hillman, ...
Single-cell RNA-sequencing and-imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade.
B Izar, L Jerby-Arnon, A Rotem, P Shah, D Liu, G Zhang, B Schilling, ...
Journal of Clinical Oncology 36 (15_suppl), 3074-3074, 2018
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
A Regev, O Rozenblatt-Rosen, B Izar, L Jerby, A Rotem
US Patent App. 16/753,039, 2020
A cancer cell program promotes T-cell exclusion and resistance to checkpoint blockade.
P Shah, M Cuoco, MJ Su, J Melms, R Leeson, A Kanodia, S Mei, JR Lin, ...
CANCER RESEARCH 80 (19), 43-43, 2020
The system can't perform the operation now. Try again later.
Articles 1–20